Literature DB >> 18180097

Statins in tumor suppression.

Antonella Sassano1, Leonidas C Platanias.   

Abstract

Statins are HMG-CoA reductase inhibitors with important cholesterol-lowering properties. The introduction of these agents in clinical medicine has had a major impact and has changed the natural history of coronary artery disease in humans. Beyond their cholesterol-lowering properties, statins exhibit important anti-inflammatory and antitumor activities. Extensive studies over the last few years have demonstrated that statins generate pro-apoptotic, growth inhibitory, and pro-differentiation responses on neoplastic cells of diverse origin. In addition, several cellular pathways activated by statins have been identified and key mechanisms involved in the generation of their antitumor effects have been characterized. Because of such in vitro effects, extensive efforts are underway to establish their utility in cancer prevention and their potential use in the treatment of certain malignancies, in combination with other agents. This review summarizes the documented effects of statins on different tumor cell types and discusses the cellular mechanisms of action of statins in malignant cells. The clinical-translational implications of the ongoing research efforts are also discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180097     DOI: 10.1016/j.canlet.2007.11.036

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

1.  Anti-Inflammatory Agents for Cancer Therapy.

Authors:  Elizabeth R Rayburn; Scharri J Ezell; Ruiwen Zhang
Journal:  Mol Cell Pharmacol       Date:  2009

2.  Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis.

Authors:  I Campia; C Lussiana; G Pescarmona; D Ghigo; A Bosia; C Riganti
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

3.  Do statins reduce patients' risk of hepatocellular carcinoma?

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

4.  Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.

Authors:  Paul J Limburg; Michelle R Mahoney; Katie L Allen Ziegler; Stephen J Sontag; Robert E Schoen; Richard Benya; Michael J Lawson; David S Weinberg; Elena Stoffel; Michael Chiorean; Russell Heigh; Joel Levine; Gary Della'Zanna; Luz Rodriguez; Ellen Richmond; Christopher Gostout; Sumithra J Mandrekar; Thomas C Smyrk
Journal:  Cancer Prev Res (Phila)       Date:  2011-01-05

5.  Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus.

Authors:  Elizabeth D Kantor; Lynn Onstad; Patricia L Blount; Brian J Reid; Thomas L Vaughan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-01-12       Impact factor: 4.254

Review 6.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

7.  Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.

Authors:  Anna Martirosyan; James W Clendening; Carolyn A Goard; Linda Z Penn
Journal:  BMC Cancer       Date:  2010-03-18       Impact factor: 4.430

8.  Effects of lovastatin on breast cancer cells: a proteo-metabonomic study.

Authors:  Jelena Klawitter; Touraj Shokati; Vanessa Moll; Uwe Christians; Jost Klawitter
Journal:  Breast Cancer Res       Date:  2010-03-05       Impact factor: 6.466

9.  Simvastatin potentiates doxorubicin activity against MCF-7 breast cancer cells.

Authors:  Benjaporn Buranrat; Wanwisa Suwannaloet; Jarinyaporn Naowaboot
Journal:  Oncol Lett       Date:  2017-08-21       Impact factor: 2.967

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.